ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
ORIC Pharmaceuticals has entered an agreement with Cancer Research UK to initiate clinical development of ORIC-259, a novel small molecule degrader targeting the previously undruggable CIP2A protein implicated in various cancers. Cancer Research UK will fully fund and manage early clinical studies, while ORIC retains an option to reacquire rights p…